AMERICAN ASSOCIATION for CANCER RESEARCH Conclusio
Post# of 151795

We observed that treatment with Leronlimab resulted in RAPID DECREASES in the presence of multiple populations of TACS in 75% of (26) Patients, which also SIGNIFICANTLY correlated with Better PFS and OS after 1-year analysis. Oh...Where Oh... Where is the FDA?

